The paper, developed by Prof Newton and colleagues at the London School of Hygiene & Tropical Medicine and the Liverpool School of Tropical Medicine, reviews the quality of medicines used in clinical trials, and suggests that tighter guidelines are needed to ensure that drugs are carefully monitored for overall quality, deterioration and evidence of counterfeit or substandard medicines enterring the distribution chain.
Read more (WorldWide Antimalarial Resistance Network (WWARN) website)